^
Association details:
| Biomarker: | CD38 expression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | mezagitamab (TAK-079) (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells
Published date:
11/06/2019
Excerpt:
Conversely, TAK-079 bound 181% more potently than daratumumab to CD38 expressed on blood B lymphocytes (e.g. MFI mean EC50 =3.6 & 6.6 nM, respectively) and 259% more potently to blood T lymphocytes (e.g. MFI mean EC50 = 9.3 & 24.2 nM, respectively)....Furthermore, bone marrow myeloma and plasma cells were completely saturated by TAK-079 and reduced at subcutaneous doses ≥ 300mg administered weekly.
DOI:
https://doi.org/10.1182/blood-2019-128238
